MXCT
MaxCyte, Inc. (MXCT) Business Model Analysis (2026)
Overall Score
Revenue Demand Quality
Gross margin remains strong at 79.4%, indicating the core product mix still supports healthy unit economics.
Revenue productivity is still modest, with price-to-sales at 4.4x and revenue per share of 0.29, suggesting the business is not yet generating high top-line scale.
Profitability Cash Generation
The company remains unprofitable, with EBIT margin at -114.8% and net profit margin at -114.8%.
Free cash flow is still negative, as shown by free cash flow yield of -17.5% and operating cash flow ratio of -2.32.
Balance Sheet Capital Efficiency
Liquidity is very strong, with a current ratio of 12.26x and quick ratio of 11.47x.
Leverage remains low, with debt-to-equity at 0.11x and debt-to-assets at 9.3%, while net debt is minimal relative to EBITDA.
Operating Efficiency Working Capital
Working capital is positive at $111.4M, but the cash conversion cycle is very long at 392.7 days, reflecting slow conversion of inventory and receivables into cash.
Inventory turnover is weak at 0.82x and days inventory outstanding is 445.7, indicating heavy inventory intensity.
Business Model Resilience
The business has a strong cash buffer and low debt, which helps resilience despite current losses.
However, the model still depends on improving operating leverage and inventory efficiency before it can be considered durable on a self-funding basis.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MaxCyte, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

